Marathon Pharmaceuticals, LLC Prepares For Launch Of New Rare Disease Treatments By Selling Non-Strategic Products To Valeant Including Isuprel And Nitropress

Sale proceeds invested into rare disease treatment pipeline

NORTHBROOK, Ill.--(BUSINESS WIRE)--Marathon Pharmaceuticals today announced that the company has made significant progress with its rare disease pipeline and expects several approvals and product launches beginning in 2016. In preparation for rolling out its new rare disease treatments, Marathon sold its portfolio of non-strategic products and will be investing proceeds of that sale back into its rare disease pipeline.

“The success of our rare disease pipeline has made it possible to divest products that don’t fit this focus in order to prepare for a new phase of our growth.”

Marathon sold a portfolio of branded hospital products to Valeant Pharmaceuticals North America, LLC including Amytal® Sodium (amobarbital sodium for injection, USP), Iprivask® (desirudin for injection), Isuprel® (isoproterenol HCl injection, USP), Nitropress® (sodium nitroprusside injection), Opium Tincture, Pepcid® (famotidine) tablets and Seconal® Sodium (secobarbital sodium capsules, USP). With the sale, Valeant assumed all responsibility for product availability and pricing.

Marathon Pharmaceuticals no longer has any responsibility for availability, pricing or orders for any of the products included in this transaction. Marathon will invest 100 percent of the proceeds of this sale to further build its pipeline of rare disease treatments.

“We believe Marathon can make a bigger difference in patients’ lives by focusing all of our resources and expertise on developing new rare disease treatments,” said Marathon’s Chairman and CEO Jeff Aronin. “The success of our rare disease pipeline has made it possible to divest products that don’t fit this focus in order to prepare for a new phase of our growth.”

Marathon recently received fast track status for a potential new treatment for Duchenne muscular dystrophy. It is also developing treatments for Huntington’s disease and adrenal cancer. Though there are more than 6,000 recognized rare diseases for which no treatment exists, many pharmaceutical companies are unwilling or unable to invest in treatments for conditions that affect fewer than 200,000 patients.

Marathon Pharmaceuticals, LLC is a biopharmaceutical company that develops new treatments for rare diseases with a focus on providing medicine to patients who currently have no treatment options. The company is developing a pipeline of treatments for rare neurological and movement disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago, New Jersey and Washington D.C. For more information, visit www.marathonpharma.com.

Help employers find you! Check out all the jobs and post your resume.